16 results
8-K
EX-2.1
INM
InMed Pharmaceuticals Inc
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
with the employment of any current or former applicant, employee, consultant, volunteer, intern or independent contractor of the Company, including, without
10-K
2021 FY
EX-2.1
INM
InMed Pharmaceuticals Inc
24 Sep 21
Annual report
7:31am
Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant, volunteer, intern or independent
10-K
2021 FY
INM
InMed Pharmaceuticals Inc
24 Sep 21
Annual report
7:31am
of the second Phase I healthy volunteer study (755-102-HV). The 755-102-HV clinical trial is a randomized, double-blind, vehicle-controlled, Phase I study
424B3
INM
InMed Pharmaceuticals Inc
22 Jul 21
Prospectus supplement
10:27am
announced initiation of enrollment of the second Phase I healthy volunteer study (755-102-HV). The 755-102-HV clinical trial is a randomized, double-blind … in accordance with a country’s requirements, clinical trial development may proceed. In addition to our recently concluded healthy volunteer treatment
424B3
w2jqbsxiuxda2v85
16 Mar 21
Prospectus supplement
12:00am
8-K
EX-99.1
ej15dx bd0n
11 Jan 21
Regulation FD Disclosure
6:03am
424B4
k1yddylgj 8kkc3l
13 Nov 20
Prospectus supplement with pricing info
8:52pm
S-1
vxzh9scwoewwy6j
19 Jun 20
IPO registration
4:59pm
DRS/A
3p7rsbp9 iz
27 May 20
Draft registration statement (amended)
12:00am
DRS
oaw3i2ai cm
13 Apr 20
Draft registration statement
12:00am
- Prev
- 1
- Next